施普善治療創(chuàng)傷性顱腦損傷（TBI）臨床療效的初步觀察
發(fā)布時(shí)間：2019-04-24 17:19
【摘要】：目的 該實(shí)驗(yàn)的目的是探討GCS評(píng)分為（7-12）分的創(chuàng)傷性顱腦損傷患者，將施普善作為標(biāo)準(zhǔn)治療方案的追加治療后，觀察其在治療期、康復(fù)期及遠(yuǎn)期三個(gè)時(shí)期的臨床效果。 研究對(duì)象與方法 2010年2月-2012年9月期間，在泰山醫(yī)學(xué)院附屬醫(yī)院神經(jīng)外科收治的GCS評(píng)分為（7-12）分范圍內(nèi)的創(chuàng)傷性顱腦損傷（TBI）患者，共60例。將60例TBI患者按照隨機(jī)分配原則分為實(shí)驗(yàn)組（35例）和對(duì)照組（25例）。實(shí)驗(yàn)組和對(duì)照組的患者除按照顱腦損傷救治指南的標(biāo)準(zhǔn)治療方案進(jìn)行治療外，實(shí)驗(yàn)組還追加相同劑量(見(jiàn)表1)施普善藥物治療。兩組都從入院治療后第30天、第90天及180天三個(gè)時(shí)期，從簡(jiǎn)易精神狀態(tài)檢查（MMSE）、處理速度指數(shù)（PSI）（WALS-第三版）、遠(yuǎn)期生活質(zhì)量評(píng)估三個(gè)方面來(lái)評(píng)價(jià)施普善藥物在創(chuàng)傷性顱腦損傷（TBI）患者中的療效。在治療期間根據(jù)副反應(yīng)量表(DOTES和TWIS)記錄的不良事件以及3個(gè)月時(shí)的死亡率作為安全性指標(biāo)評(píng)定本藥物的安全性。用SPSS13.0統(tǒng)計(jì)軟件進(jìn)行統(tǒng)計(jì)學(xué)分析，計(jì)量資料用x s表示，組間比較行t檢驗(yàn)，以p0.05為差異有統(tǒng)計(jì)學(xué)意義。 結(jié)果 ①符合入組條件患者為60例，因故中途退出研究者7例，因此共有53例樣本納入本研究結(jié)果。 ②通過(guò)對(duì)實(shí)驗(yàn)組和對(duì)照組兩組間比較，在治療后的第30天、第90天和第180天三個(gè)時(shí)期對(duì)患者行MMSE、PSI和遠(yuǎn)期生活質(zhì)量三個(gè)指標(biāo)進(jìn)行測(cè)試；對(duì)照組和實(shí)驗(yàn)組在治療的第30天、第90天及180天比較分析均有差異性（P＜0.05），且具有統(tǒng)計(jì)學(xué)意義。特別是在遠(yuǎn)期生活質(zhì)量方面，第180天時(shí)，實(shí)驗(yàn)組平均分為（4.74±0.51），對(duì)照組平均分為（4.09±0.43），兩組相比具有明顯差異性。 ③治療3個(gè)月共死亡患者7例，死因均為肺部感染。實(shí)驗(yàn)組死亡患者4例，占11.4%；對(duì)照組死亡患者3例，占12%，，兩組間死亡率比較無(wú)明顯差異性。 結(jié)論 施普善(Cerebrolysin,腦活素)在作為追加治療的GCS評(píng)分為（7-12）分的創(chuàng)傷性顱腦損傷患者中，在治療后的第30天、第90天及180天均能明顯提高患者在MMSE、PSI和遠(yuǎn)期生活質(zhì)量三個(gè)指標(biāo)中的評(píng)分，對(duì)患者的遠(yuǎn)期生活質(zhì)量效果尤為顯著，經(jīng)過(guò)初步驗(yàn)證施普善是一種有效、安全的藥物。對(duì)創(chuàng)傷性顱腦損傷患者的臨床治療提供了一種可靠的臨床治療方案。
[Abstract]:Objective the purpose of this experiment was to investigate the traumatic brain injury patients whose GCS score was (7? 12), and to observe the therapeutic period of Spusanne as a standard treatment regimen. Clinical effects of convalescence and long-term period. Participants and methods from February 2010 to September 2012, 60 patients with traumatic craniocerebral injury (TBI) were enrolled in the neurosurgery department of the affiliated Hospital of Taishan Medical College. Sixty patients with TBI were divided into experimental group (n = 35) and control group (n = 25) according to the principle of random distribution. The patients in the experimental group and the control group were treated with the same dosage (see Table 1) in addition to the standard treatment plan in the treatment guidelines for craniocerebral injury (see Table 1). From the 30th, 90th and 180th days after admission, the (MMSE), processing velocity index (PSI) (WALS- 3rd edition) was measured from the mini-mental state examination in both groups. Long-term assessment of quality of life (QOL) was used to evaluate the efficacy of Spusa in traumatic craniocerebral injury (TBI) patients. The safety of the drug was evaluated according to adverse events recorded by DOTES and TWIS during treatment and mortality at 3 months. SPSS13.0 statistical software was used for statistical analysis. The measurement data were expressed by x / s. T-test was used to compare the data between groups, and the difference was statistically significant with p0.05 as the difference. Results (1) 60 patients met the criteria of admission and 7 patients dropped out of the study. Therefore, 53 samples were included in this study. (2) MMSE,PSI and long-term quality of life (QOL) were measured on the 30th day, 90th day and 180th day after treatment between the experimental group and the control group. There was significant difference between the control group and the experimental group on the 30th, 90th and 180th day of treatment (P < 0.05). On the 180th day, the average score of the experimental group was (4.74 鹵0.51), that of the control group was (4.09 鹵0.43), there was significant difference between the two groups. 3There were 7 cases of death after 3 months treatment, all the causes of death were pulmonary infection. There were 4 dead patients (11.4%) in the experimental group and 3 dead patients (12%) in the control group. There was no significant difference in the mortality between the two groups. Conclusion in the patients with traumatic craniocerebral injury (TBI) whose GCS score (7? 12) as supplementary treatment, Cerebrolysin, can significantly improve the level of MMSE, on the 30th, 90th and 180th day after the treatment. [WT5 "HZ] conclusion [WT5" BZ] [WT5 "BZ] The score of PSI and long-term quality of life (QOL) is especially significant for the patients with long-term quality of life. It has been preliminarily proved that Spusanne is an effective and safe drug. It provides a reliable clinical treatment for traumatic craniocerebral injury patients.
【學(xué)位授予單位】：泰山醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類(lèi)號(hào)】：R651.15
[Abstract]:Objective the purpose of this experiment was to investigate the traumatic brain injury patients whose GCS score was (7? 12), and to observe the therapeutic period of Spusanne as a standard treatment regimen. Clinical effects of convalescence and long-term period. Participants and methods from February 2010 to September 2012, 60 patients with traumatic craniocerebral injury (TBI) were enrolled in the neurosurgery department of the affiliated Hospital of Taishan Medical College. Sixty patients with TBI were divided into experimental group (n = 35) and control group (n = 25) according to the principle of random distribution. The patients in the experimental group and the control group were treated with the same dosage (see Table 1) in addition to the standard treatment plan in the treatment guidelines for craniocerebral injury (see Table 1). From the 30th, 90th and 180th days after admission, the (MMSE), processing velocity index (PSI) (WALS- 3rd edition) was measured from the mini-mental state examination in both groups. Long-term assessment of quality of life (QOL) was used to evaluate the efficacy of Spusa in traumatic craniocerebral injury (TBI) patients. The safety of the drug was evaluated according to adverse events recorded by DOTES and TWIS during treatment and mortality at 3 months. SPSS13.0 statistical software was used for statistical analysis. The measurement data were expressed by x / s. T-test was used to compare the data between groups, and the difference was statistically significant with p0.05 as the difference. Results (1) 60 patients met the criteria of admission and 7 patients dropped out of the study. Therefore, 53 samples were included in this study. (2) MMSE,PSI and long-term quality of life (QOL) were measured on the 30th day, 90th day and 180th day after treatment between the experimental group and the control group. There was significant difference between the control group and the experimental group on the 30th, 90th and 180th day of treatment (P < 0.05). On the 180th day, the average score of the experimental group was (4.74 鹵0.51), that of the control group was (4.09 鹵0.43), there was significant difference between the two groups. 3There were 7 cases of death after 3 months treatment, all the causes of death were pulmonary infection. There were 4 dead patients (11.4%) in the experimental group and 3 dead patients (12%) in the control group. There was no significant difference in the mortality between the two groups. Conclusion in the patients with traumatic craniocerebral injury (TBI) whose GCS score (7? 12) as supplementary treatment, Cerebrolysin, can significantly improve the level of MMSE, on the 30th, 90th and 180th day after the treatment. [WT5 "HZ] conclusion [WT5" BZ] [WT5 "BZ] The score of PSI and long-term quality of life (QOL) is especially significant for the patients with long-term quality of life. It has been preliminarily proved that Spusanne is an effective and safe drug. It provides a reliable clinical treatment for traumatic craniocerebral injury patients.
【學(xué)位授予單位】：泰山醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類(lèi)號(hào)】：R651.15
【參考文獻(xiàn)】
相關(guān)期刊論文 前5條
1 劉衛(wèi)平,章翔,易聲禹,方宏,費(fèi)舟,付洛安,程光,顧建文;大鼠急性顱腦損傷后腦微循環(huán)的變化[J];第四軍醫(yī)大學(xué)學(xué)報(bào);2000年12期
2 高峰;崔o
本文編號(hào)：2464635
本文鏈接：http://sikaile.net/yixuelunwen/jjyx/2464635.html
最近更新
教材專(zhuān)著
